Physician profile
Sergio Collazo
NPI 1619531027
$3,313.42
in general payments reported to CMS, 2019-2025
22 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $236 · 2021: $535 · 2022: $513 · 2023: $446 · 2024: $824 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $797.00 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $681.00 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $486.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $305.36 | 2021-2025 | |
| Abbvie INC. | $141.40 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $121.27 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $120.03 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Genentech USA, INC. | $112.56 | 2019 | |
| Exact Sciences Corporation | $101.45 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.07 | 2020-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $83.97 | 2021-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $65.59 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $30.17 | 2021 | |
| Hologic Sales and Service, LLC | $26.31 | 2023 | Affirm Prone Biopsy System, Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $21.89 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $20.73 | 2022 | |
| Averitas Pharma INC. | $19.99 | 2024 | Qutenza |
| Astellas Pharma US INC | $19.71 | 2024 | Veozah |
| Pfizer INC. | $19.46 | 2025 | |
| Eisai INC. | $18.87 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.70 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Collazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.